AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2015

Jan 13, 2015

30583_dirs_2015-01-13_29b2c94d-e039-45a0-b2be-58953301e9ef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2015-01-09

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-01-09	Common Stock	S	2000	$94.1429	Disposed	225157	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	43195	Indirect

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed November 6, 2014

F2: The price in column 4 is an average weighted price. The price actually received ranged from $93.14 to $94.96. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.

F3: The reporting person an his spouse act as trustees for the Bienaime Family Trust